drugset / Trial / NCT07166367
Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to study the efficacy of ASLAN 001 plus capecitabine for previously irradiated, progressing CNS metastases for HER2+ breast cancer patients.
Timeline
- Start
- 2016-08-11
- Primary completion
- 2020-01-14
- Completion
- 2020-01-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Varlitinib | Small molecule | 400 mg | Oral |